Guillaume Escure

Lille, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Inflammatory bone marrow microenvironment impairs the therapeutic effect of daratumumab-lenalidomide in multiple myeloma.

Inflammatory bone marrow microenvironment impairs the therapeutic effect of daratumumab-lenalidomide in multiple myeloma.

Journal: Biomarker research

Published: May 24, 2026

Real-world safety and efficacy of apixaban versus standard thromboprophylaxis in newly diagnosed multiple myeloma: Insights from a multicentre retrospective cohort study.

Real-world safety and efficacy of apixaban versus standard thromboprophylaxis in newly diagnosed multiple myeloma: Insights from a multicentre retrospective cohort study.

Journal: British journal of haematology

Published: March 14, 2026

Clinical benefit of tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma: real-world data from the EarlyMIND study.

Clinical benefit of tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma: real-world data from the EarlyMIND study.

Journal: Haematologica

Published: December 10, 2024

Genomic profiling of mycosis fungoides identifies patients at high risk of disease progression.

Genomic profiling of mycosis fungoides identifies patients at high risk of disease progression.

Journal: Blood advances

Published: December 12, 2023

Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies: a national retrospective study.

Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies: a national retrospective study.

Journal: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases

Published: November 21, 2023

Small myeloid subclones are present at diagnosis of multiple myeloma in patients who develop secondary myelodysplastic syndromes.

Small myeloid subclones are present at diagnosis of multiple myeloma in patients who develop secondary myelodysplastic syndromes.

Journal: Haematologica

Published: August 08, 2023

Cutaneous mucormycosis in an immunosuppressed patient.

Cutaneous mucormycosis in an immunosuppressed patient.

Journal: Annales de dermatologie et de venereologie

Published: November 27, 2022

Tolerance of bradykinin-releasing drugs in patients with acquired C1 inhibitor deficiency: a case series and review of the literature.

Tolerance of bradykinin-releasing drugs in patients with acquired C1 inhibitor deficiency: a case series and review of the literature.

Journal: European journal of dermatology : EJD

Published: May 06, 2022

Current state and next-generation CAR-T cells in multiple myeloma.

Current state and next-generation CAR-T cells in multiple myeloma.

Journal: Blood reviews

Published: October 03, 2021

Bispecific antibodies in multiple myeloma

Bispecific antibodies in multiple myeloma

Journal: Bulletin du cancer

Published: July 12, 2021

Treatment with temozolomide and ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL).

Treatment with temozolomide and ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL).

Journal: European journal of haematology

Published: February 28, 2021

Case Report: Two Cases of Cryptosporidiosis in Heavily Pretreated Patients With Myeloma.

Case Report: Two Cases of Cryptosporidiosis in Heavily Pretreated Patients With Myeloma.

Journal: Clinical lymphoma, myeloma & leukemia

Published: December 17, 2020

Showing 1-12 of 14

Last Updated: 09/26/2026